Research Center for Advanced Medicine - MedFUTURE, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Oncology, The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, Maryland.
Cancer Res. 2023 Jun 2;83(11):1762-1767. doi: 10.1158/0008-5472.CAN-22-3739.
The ubiquitin-proteasome system (UPS) is responsible for up to 90% of intracellular protein degradation. Alterations in UPS are extensively involved in the development and advancement of malignant pathologies. Thus, the components of the UPS can become potential targets for cancer therapeutics. KPC1 is an E3 ubiquitin ligase component of the UPS that regulates key pathways and processes in cancer. KPC1 sustains the ubiquitination of cytoplasmic p27, determining its elimination and transition between cell-cycle phases. KPC1 also regulates NF-κB signaling by inducing ubiquitination of p105 to allow subsequent proteasomal processing to the functional form p50. It has been shown that the KPC1-p50 duo is reduced or absent in multiple malignancies and that therapeutic reinforcement of the functional axis can exhibit significant tumor suppressor activity. Here, we highlight the potential role of KPC1 as a tumor suppressor by fully describing its crucial role in p27 signaling and the canonical NF-κB pathway.
泛素-蛋白酶体系统 (UPS) 负责高达 90%的细胞内蛋白质降解。UPS 的改变广泛涉及恶性病理的发展和进展。因此,UPS 的成分可以成为癌症治疗的潜在靶点。KPC1 是 UPS 的 E3 泛素连接酶成分,调节癌症中的关键途径和过程。KPC1 维持细胞质 p27 的泛素化,决定其消除和细胞周期相之间的转变。KPC1 还通过诱导 p105 的泛素化来调节 NF-κB 信号,从而允许随后的蛋白酶体加工成功能性形式 p50。已经表明,在多种恶性肿瘤中,KPC1-p50 二聚体减少或缺失,并且功能轴的治疗强化可以表现出显著的肿瘤抑制活性。在这里,我们通过充分描述其在 p27 信号和经典 NF-κB 途径中的关键作用,强调 KPC1 作为肿瘤抑制因子的潜在作用。